Research
Hormonal
Genetic variants in GLP1R (e.g., rs6923761), GIPR (e.g., rs2287019, rs10423928), and TCF7L2 (rs7903146) significantly influence individual response to tirzepatide, affecting glycemic control, weight loss, and side effect profiles.
Your genes can affect how well tirzepatide works for you. If you have certain genetic variants, you might need a different dose or might experience different side effects. Talk to your doctor about genetic testing to personalize your treatment.
ModerateQualifiesMEDIUM confidence
Polymorphisms in GLP1R and GIPR may affect receptor expression levels, signaling efficiency, and downstream metabolic pathways, thereby influencing drug responsiveness... TCF7L2 rs7903146 is hypothesized to affect tirzepatide response through combined pancreatic and adipose mechanisms...
Why this rating
Based on observational studies, GWAS, and mechanistic hypotheses; direct clinical trial data for tirzepatide specifically is limited.
Source
Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis
Zihang Song et al. · Pharmaceuticals · 2025
DOI 10.3390/ph18091261
narrative_reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and weight loss compared to GLP-1 receptor agonists alone, while offering cardioprotective benefits through lipid lowering and anti-inflammatory mechanisms.Good
- Tirzepatide may reduce the risk of atherosclerosis progression through lipid-lowering, anti-inflammatory, and improved insulin sensitivity mechanisms, offering cardioprotective benefits beyond glycemic control.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →